Cytek Biosciences (NASDAQ:CTKB) Hits New 1-Year High – Should You Buy?

Posted by Brian Himes on Oct 8th, 2026

Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $6.21 and last traded at $5.9950, with a volume of 45889 shares changing hands. The stock had previously closed at $6.09.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CTKB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a report on Monday, September 21st. Morgan Stanley set a $5.00 price objective on Cytek Biosciences in a research note on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.56.

Check Out Our Latest Analysis on CTKB

Cytek Biosciences Trading Down 0.7%

The stock has a market capitalization of $694.09 million, a PE ratio of -8.61 and a beta of 1.16. The business’s 50 day moving average is $4.91 and its 200 day moving average is $4.54.

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). The company had revenue of $48.14 million for the quarter, compared to analyst estimates of $47.31 million. Cytek Biosciences had a negative net margin of 38.98% and a negative return on equity of 12.40%. As a group, analysts anticipate that Cytek Biosciences, Inc. will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytek Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its holdings in shares of Cytek Biosciences by 86.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,144 shares of the company’s stock valued at $26,000 after purchasing an additional 2,388 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Cytek Biosciences during the second quarter valued at approximately $29,000. AXQ Capital LP boosted its stake in shares of Cytek Biosciences by 43.6% during the second quarter. AXQ Capital LP now owns 28,299 shares of the company’s stock valued at $125,000 after purchasing an additional 8,591 shares in the last quarter. Two Sigma Securities LLC purchased a new position in Cytek Biosciences during the second quarter valued at approximately $50,000. Finally, Pallas Capital Advisors LLC purchased a new position in Cytek Biosciences during the second quarter valued at approximately $50,000. 69.46% of the stock is owned by institutional investors.

Cytek Biosciences Company Profile

(Get Free Report)

Cytek Biosciences, Inc develops and manufactures cell analysis technologies for research, clinical, and biopharmaceutical applications. The company is best known for its full-spectrum flow cytometry platform, which captures a broader range of fluorescent light signals than conventional flow cytometers and is designed to support the analysis of complex cell populations.

Cytek’s product portfolio includes the Aurora and Northern Lights flow cytometers, which are available in configurations intended for a range of laboratory requirements.